Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 101 items for :

  • "antithyroid drugs" x
Clear All
Jonah Robinson Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Jonah Robinson in
Google Scholar
PubMed Close
,
Max Richardson Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Max Richardson in
Google Scholar
PubMed Close
,
Janis Hickey British Thyroid Foundation, Harrogate, UK

Search for other papers by Janis Hickey in
Google Scholar
PubMed Close
,
Andy James Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Andy James in
Google Scholar
PubMed Close
,
Simon H. Pearce Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Simon H. Pearce in
Google Scholar
PubMed Close
,
Steve G. Ball Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Steve G. Ball in
Google Scholar
PubMed Close
,
Richard Quinton Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Richard Quinton in
Google Scholar
PubMed Close
,
Margaret Morris Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Margaret Morris in
Google Scholar
PubMed Close
,
Margaret Miller Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Margaret Miller in
Google Scholar
PubMed Close
, and
Petros Perros Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, Harrogate, UK

Search for other papers by Petros Perros in
Google Scholar
PubMed Close

Introduction Hyperthyroidism affects approximately 1% of the adult population [ 1 , 2 ]. Antithyroid drugs are commonly used to control hyperthyroidism [ 3 , 4 ]. Assuming an incidence of Graves' disease in Europe of 21/100,000 per year [ 5

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000367990
Volume/Issue:
Volume 3: Issue 4
Free access
Spiros Karras Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece

Search for other papers by Spiros Karras in
Google Scholar
PubMed Close
and
Gerasimos E. Krassas Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece

Search for other papers by Gerasimos E. Krassas in
Google Scholar
PubMed Close

Graves’ disease (GD) can occur during the postpartum period, as a relapse of previous GD or a newly diagnosed case with no apparent thyroid disease background. In this case, antithyroid drugs (ATD) are considered the treatment of choice by most

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000336595
Volume/Issue:
Volume 1: Issue 1
Free access
Meihua Jin Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine and School of Medicine, Seoul, Republic of Korea

Search for other papers by Meihua Jin in
Google Scholar
PubMed Close
,
Ahreum Jang Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
Division of Endocrinology and Metabolism, Department Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea

Search for other papers by Ahreum Jang in
Google Scholar
PubMed Close
,
Chae A Kim Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Search for other papers by Chae A Kim in
Google Scholar
PubMed Close
,
Tae Yong Kim Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Search for other papers by Tae Yong Kim in
Google Scholar
PubMed Close
,
Won Bae Kim Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Search for other papers by Won Bae Kim in
Google Scholar
PubMed Close
,
Young Kee Shong Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Search for other papers by Young Kee Shong in
Google Scholar
PubMed Close
,
Min Ji Jeon Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Search for other papers by Min Ji Jeon in
Google Scholar
PubMed Close
, and
Won Gu Kim Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Search for other papers by Won Gu Kim in
Google Scholar
PubMed Close

gland ( 1 , 2 ). Current treatment options for patients with Graves’ hyperthyroidism include antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, and surgery ( 1 , 3 , 4 ). Although geographical difference exists, ATD is the preferred first

Article Type:
Research Article
Collections:
Hyperthyroidism and thyrotoxicosis
DOI:
https://doi.org/10.1530/ETJ-22-0226
Volume/Issue:
Volume 12: Issue 2
Open access
Pei-Wen Wang Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine

Search for other papers by Pei-Wen Wang in
Google Scholar
PubMed Close
,
I-Ya Chen Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine

Search for other papers by I-Ya Chen in
Google Scholar
PubMed Close
,
Suh-Hang Hank Juo Department of Medical Research, Kaohsiung Medical University Hospital and Graduate Institute of Medical Genetics, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC

Search for other papers by Suh-Hang Hank Juo in
Google Scholar
PubMed Close
,
Edward Hsi Department of Medical Research, Kaohsiung Medical University Hospital and Graduate Institute of Medical Genetics, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC

Search for other papers by Edward Hsi in
Google Scholar
PubMed Close
,
Rue-Tsuan Liu Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine

Search for other papers by Rue-Tsuan Liu in
Google Scholar
PubMed Close
, and
Ching-Jung Hsieh Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine

Search for other papers by Ching-Jung Hsieh in
Google Scholar
PubMed Close

Introduction For patients with Graves’ disease (GD), there are three choices of treatment, none of which is perfect. The primary goal of antithyroid drug therapy is to temporarily restore the patient to the euthyroid state while awaiting a

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000342621
Volume/Issue:
Volume 1: Issue 4
Free access
Hirotoshi Nakamura Kuma Hospital, Kobe, Japan

Search for other papers by Hirotoshi Nakamura in
Google Scholar
PubMed Close
,
Akane Ide Kuma Hospital, Kobe, Japan

Search for other papers by Akane Ide in
Google Scholar
PubMed Close
,
Takumi Kudo Kuma Hospital, Kobe, Japan

Search for other papers by Takumi Kudo in
Google Scholar
PubMed Close
,
Eijun Nishihara Kuma Hospital, Kobe, Japan

Search for other papers by Eijun Nishihara in
Google Scholar
PubMed Close
,
Mitsuru Ito Kuma Hospital, Kobe, Japan

Search for other papers by Mitsuru Ito in
Google Scholar
PubMed Close
, and
Akira Miyauchi Kuma Hospital, Kobe, Japan

Search for other papers by Akira Miyauchi in
Google Scholar
PubMed Close

Introduction Agranulocytosis (AG) is one of the most serious complications of antithyroid drug (ATD) therapy for Graves' disease. It is rare, but if its discovery is delayed and severe infection develops, a lethal outcome can happen [ 1 ]. In

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000448586
Volume/Issue:
Volume 5: Issue 4
Open access
Shakeel Kautbally Divisions of Endocrinology and Nutrition, Université Catholique de Louvain, Brussels, Belgium

Search for other papers by Shakeel Kautbally in
Google Scholar
PubMed Close
,
Orsalia Alexopoulou Divisions of Endocrinology and Nutrition, Université Catholique de Louvain, Brussels, Belgium

Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed Close
,
Chantal Daumerie Divisions of Endocrinology and Nutrition, Université Catholique de Louvain, Brussels, Belgium

Search for other papers by Chantal Daumerie in
Google Scholar
PubMed Close
,
François Jamar Divisions of Nuclear Medicine, Université Catholique de Louvain, Brussels, Belgium

Search for other papers by François Jamar in
Google Scholar
PubMed Close
,
Michel Mourad Divisions of Endocrine Surgery, St. Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium

Search for other papers by Michel Mourad in
Google Scholar
PubMed Close
, and
Dominique Maiter Divisions of Endocrinology and Nutrition, Université Catholique de Louvain, Brussels, Belgium

Search for other papers by Dominique Maiter in
Google Scholar
PubMed Close

second-line treatments, at least in Europe, in case of unsuccessful therapy with antithyroid drugs (ATD), disease relapse, or drug intolerance [ 1 ]. Surgery should consist of a near total thyroidectomy (TTx), which leads to a reduced risk of relapse, as

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000339473
Volume/Issue:
Volume 1: Issue 2
Free access
Sun Mi Park Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Search for other papers by Sun Mi Park in
Google Scholar
PubMed Close
,
Yoon Young Cho Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Search for other papers by Yoon Young Cho in
Google Scholar
PubMed Close
,
Ji Young Joung Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Search for other papers by Ji Young Joung in
Google Scholar
PubMed Close
,
Seo Young Sohn Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Search for other papers by Seo Young Sohn in
Google Scholar
PubMed Close
,
Sun Wook Kim Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Search for other papers by Sun Wook Kim in
Google Scholar
PubMed Close
, and
Jae Hoon Chung Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Search for other papers by Jae Hoon Chung in
Google Scholar
PubMed Close

Introduction As antithyroid drugs (ATD) still remain the preferred modality of treatment for Graves' disease [ 1 , 2 ], clinical competence and appropriate management taking into account an array of clinical and laboratory features related to

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000375261
Volume/Issue:
Volume 4: Issue 1
Free access
Hiroyuki Iwaki Division of Endocrinology, Department of Internal Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan

Search for other papers by Hiroyuki Iwaki in
Google Scholar
PubMed Close
,
Kenji Ohba Medical Education Center, Hamamatsu University School of Medicine, Hamamatsu, Japan

Search for other papers by Kenji Ohba in
Google Scholar
PubMed Close
,
Eisaku Okada Department of Community Health and Preventive Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

Search for other papers by Eisaku Okada in
Google Scholar
PubMed Close
,
Takeshi Murakoshi Obstetrics and Gynecology, Maternal and Perinatal Care Center, Seirei Hamamatsu General Hospital, Hamamatsu, Japan

Search for other papers by Takeshi Murakoshi in
Google Scholar
PubMed Close
,
Yumiko Kashiwabara Division of Endocrinology, Department of Internal Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan

Search for other papers by Yumiko Kashiwabara in
Google Scholar
PubMed Close
,
Chiga Hayashi Division of Endocrinology, Department of Internal Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan

Search for other papers by Chiga Hayashi in
Google Scholar
PubMed Close
,
Akio Matsushita Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

Search for other papers by Akio Matsushita in
Google Scholar
PubMed Close
,
Shigekazu Sasaki Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

Search for other papers by Shigekazu Sasaki in
Google Scholar
PubMed Close
,
Takafumi Suda Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

Search for other papers by Takafumi Suda in
Google Scholar
PubMed Close
,
Yutaka Oki Department of Metabolism and Endocrinology, Hamamatsu-Kita Hospital, Hamamatsu, Japan

Search for other papers by Yutaka Oki in
Google Scholar
PubMed Close
, and
Rieko Gemma Division of Endocrinology, Department of Internal Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan

Search for other papers by Rieko Gemma in
Google Scholar
PubMed Close

Introduction Antithyroid drugs (ATDs) are the mainstay of medical treatment for Graves’ hyperthyroidism, occurring in approximately 0.2% during pregnancy [ 1 ]. All ATDs tend to be more potent in the fetus than in the mother [ 2 - 4 ]. ATD

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000509324
Volume/Issue:
Volume 10: Issue 5
Free access
Christiaan F Mooij Department of Pediatric Endocrinology, Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands

Search for other papers by Christiaan F Mooij in
Google Scholar
PubMed Close
,
Timothy D Cheetham Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK
Department of Pediatric Endocrinology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK

Search for other papers by Timothy D Cheetham in
Google Scholar
PubMed Close
,
Frederik A Verburg Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands

Search for other papers by Frederik A Verburg in
Google Scholar
PubMed Close
,
Anja Eckstein Department of Ophthalmology, University Duisburg Essen, Essen, Germany

Search for other papers by Anja Eckstein in
Google Scholar
PubMed Close
,
Simon H Pearce Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK
Endocrine Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK

Search for other papers by Simon H Pearce in
Google Scholar
PubMed Close
,
Juliane Léger Department of Pediatric Endocrinology and Diabetes, Reference Center for Rare Endocrine Growth and Development Diseases, Endo-ERN HCP, Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, University of Paris, NeuroDiderot Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France

Search for other papers by Juliane Léger in
Google Scholar
PubMed Close
, and
A S Paul van Trotsenburg Department of Pediatric Endocrinology, Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands

Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed Close

Introduction Purpose and scope of guideline Hyperthyroidism caused by Graves’ disease (GD) is a relatively rare disease in children. Although treatment options are the same as in adults – antithyroid drugs (ATD), radioactive iodine (RAI

Article Type:
Other
Collections:
Pediatric thyroid diseases
DOI:
https://doi.org/10.1530/ETJ-21-0073
Volume/Issue:
Volume 11: Issue 1
Open access
Suvi Turunen Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, Oulu, Finland

Search for other papers by Suvi Turunen in
Google Scholar
PubMed Close
,
Marja Vääräsmäki Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, Oulu, Finland

Search for other papers by Marja Vääräsmäki in
Google Scholar
PubMed Close
,
Maarit Leinonen Information Services Department, Finnish Institute of Health and Welfare, Helsinki, Finland

Search for other papers by Maarit Leinonen in
Google Scholar
PubMed Close
,
Mika Gissler Information Services Department, Finnish Institute of Health and Welfare, Helsinki, Finland
Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

Search for other papers by Mika Gissler in
Google Scholar
PubMed Close
,
Tuija Männistö Northern Finland Laboratory Centre Nordlab, Oulu, Department of Neurobiology, Care Sciences and Society, Finland Karolinska Institute, Stockholm, Sweden

Search for other papers by Tuija Männistö in
Google Scholar
PubMed Close
, and
Eila Suvanto Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, Oulu, Finland

Search for other papers by Eila Suvanto in
Google Scholar
PubMed Close

the potential benefits outweigh the potential harms [ 2 ]. Current American and European guidelines recommend treating overt maternal hypothyroidism with levothyroxine (LT4) and overt hyperthyroidism with antithyroid drugs (ATDs) including

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000515125
Volume/Issue:
Volume 10: Issue 3
Free access